PHIGENIX, INC.
Diagnostic tests and targeted therapies for prostate and breast cancer based on PAX2 and EN2 oncogene inhibition
- Sector
- Biotech
- Headquarters
- ATLANTA, GA
- Latest Form D
- $842K, Aug 2015
- Total capital
- $842K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $842K
- 1 Form D · last Aug 2015
- 134 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 7 pending · first 2014
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$842K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carlton D. Donald, Ph.DExecutive Officer, DirectorNamed in SEC Form D filings
- CYNTHIA N. DAYDirectorNamed in SEC Form D filings
- KENNETH E. ROBINSON, M.D.DirectorNamed in SEC Form D filings
- RICHARD A. ROY, M.D.DirectorNamed in SEC Form D filings
- WENNIFER H. DONALDExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 9- GrantedTargeting PAX2 For The Treatment Of Breast CancerUSPTOUS 12,064,403
- PendingTargeting PAX2 For The Treatment Of Breast CancerUSPTOApplication 16573940
- PendingCompositions And Methods For Monitoring And Detecting Cancerous ConditionsUSPTOApplication 14362567
Show all 9 patent records
- Targeting PAX2 For The Treatment Of Breast CancerAug 20, 2024 · US 12,064,403Granted
- Targeting PAX2 For The Treatment Of Breast CancerMar 19, 2020 · Application 16573940Pending
- Compositions And Methods For Monitoring And Detecting Cancerous ConditionsOct 30, 2014 · Application 14362567Pending
- Targeting EN2, PAX2, And/or DEFB1 For Treatment Of Prostate ConditionsMay 15, 2014 · Application 14157231Pending
- Targeting EN2, PAX2, And/or DEFB1 For Treatment Of Prostate ConditionsMay 13, 2014 · US 8,722,643Granted
- Targeting EN2, PAX2, And/or DEFB1 For Treatment Of Prostate ConditionsApplication PCTUS2011063298Pending
- Compositions And Methods For Monitoring And Detecting Cancerous ConditionsApplication PCTUS2011063292Pending
- Targeting PAX2 For The Treatment Of Breast CancerApplication PCTUS2010024740Pending
- Detecting PAX2 For The Diagnosis Of Breast CancerApplication PCTUS2009054913Pending
Related companies, and why
- BullFrog AI Holdings, Inc.Similar federal contract value in Biotech · null in contracts
- Maxymune Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Kylix Bio, Inc.Similar federal contract value in Biotech · null in contracts
- PA Options for Wellness, Inc.Similar federal contract value in Biotech · null in contracts
- BRT Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
- Vogenx, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .